Nuclear Transcription Factor Y Subunit Beta (NFYB) is a critical component of the heterotrimeric NF-Y transcription factor complex (comprising NFYA, NFYB, and NFYC) that specifically recognizes and binds to the CCAAT box motif in eukaryotic promoters. Emerging research highlights NFYB as a pivotal driver in oncogenesis, metabolic reprogramming, and chemotherapy resistance across multiple solid tumors, making it an attractive target for novel cancer therapeutics, including protein-protein interaction (PPI) inhibitors and targeted protein degraders (PROTACs).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NFYB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant NFYB Protein (Full Length) High purity (>95% by SDS-PAGE), Endotoxin <1.0 EU/μg. Sequence Verified. Theoretical MW ~22.8 kDa. |
View NFYB Products |
| Gene Delivery | NFYB Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View NFYB Products |
| Benchmark Ab | Anti-NFYB Recombinant Antibody Recombinant positive control for Western Blot, IP, and ELISA. |
View NFYB Products |
| Validator | NFYB siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View NFYB Products |
| Related Target A | NFYA Essential partner subunit forming the active CCAAT-binding heterotrimer. |
View NFYA Products |
| Related Target B | NFYC Heterotrimeric partner; interacts directly with NFYB to form the histone-like dimer platform. |
View NFYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting functional NF-Y heterotrimer complex | Recombinant NFYA, NFYB, and NFYC subunits available with verified sequence identity and high purity (>95%) for in vitro assembly |
| High-throughput screening for protein-protein interaction (PPI) inhibitors | Low-endotoxin, carrier-free recombinant NFYB and NFYC proteins optimized for assay stability |
| Lack of reliable control antibodies for target validation | Recombinant Sequence-Verified Anti-NFYB antibody ensures high specificity without batch-to-batch variation |
| Off-target effects in RNAi-mediated validation | Multi-sequence siRNA pool designed for high knockdown efficiency with minimal off-target risks |
Live NFYB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NFYB therapeutics is intensifying, with major players shifting focus from traditional global transcriptional modulation to targeted disruption of the NF-Y trimeric complex. Because transcription factors have historically been classified as "undruggable," the next wave of R&D is targeting the specific protein-protein interaction (PPI) interface between NFYB and NFYC, as well as developing selective PROTACs to induce ubiquitination and degradation of the NFYB subunit.
Overexpression of NFYB is strongly associated with poor prognosis and drug resistance in ovarian, colorectal, and triple-negative breast cancers. By selectively disrupting the assembly of the NF-Y complex, researchers aim to downregulate critical cell-cycle regulators (such as Cyclin B1 and CDK1) and anti-apoptotic genes, sensitizing resistant tumor cells to standard chemotherapies.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic & Biotech Consortia | Ovarian Cancer, Colorectal Cancer | Trimerization Disruption Assay (Need purified NFYB/NFYC proteins) |
| PROTAC / Degrader | Targeted Therapeutics Startups | Solid Tumors, Drug-Resistant Cancers | Target Degradation Verification (Need high-specificity NFYB antibodies & siRNA) |
| Gene Therapy / RNAi | RNA Therapeutics Developers | Advanced Carcinomas | Knockdown Efficiency Validation (Need validated NFYB siRNA & Lentivirus) |